By Mark Watkins
Research analysts at Northland Securities initiated coverage on shares of CONMED (NASDAQ:CNMD) in a report released on Thursday. The firm set an “outperform” rating and a $65.00 price target on the stock. Northland Securities’ price objective would indicate a potential upside of 21.61% from the company’s current price.
A number of other firms have also recently commented on CNMD. Analysts at Zacks upgraded shares of CONMED from a “sell” rating to a “hold” rating in a research note on Tuesday, May 5th. Analysts at Deutsche Bank initiated coverage on shares of CONMED in a research note on Monday, May 4th. They set a “buy” rating and a $63.00 price target on the stock. Analysts at Ladenburg Thalmann downgraded shares of CONMED from a “buy” rating to a “neutral” rating and set a $55.00 price target on the stock in a research note on Friday, April 24th. Finally, analysts at Piper Jaffray reiterated a “neutral” rating and set a $51.00 price target (up previously from $47.00) on shares of CONMED in a research note on Thursday, April 23rd. Three analysts have rated the stock with a hold rating and five have given a buy rating to the company. CONMED has an average rating of “Buy” and a consensus target price of $56.38. 